



510(K) Submission for  
**UCP Rapid™ Drug Screening TCA, PPX Tests**

**AUG 21 2006**

**10. 510(K) SUMMARY**

This summary of safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21CFR 807.92.

The Assigned 510(k) number is

K061457

**Submitter:**

UCP Biosciences, Inc  
1445 Koll Circle, Ste 111  
San Jose, CA 95014  
Tel: 408-392-0064  
Fax: 408-392-0163

**Date:**

May 22, 2006

**Contact Person:**

Dr. Nancy Chen

**Trade Name:**

UCP Rapid™ Drug Screening Tricyclic Antidepressant Test Strips  
UCP Rapid™ Drug Screening Tricyclic Antidepressant Test  
Devices  
UCP Rapid™ Drug Screening Propoxyphene Test Strips  
UCP Rapid™ Drug Screening Propoxyphene Test Devices

**Common Name:**

Tricyclic Antidepressant Test System  
Propoxyphene Test System

**Product Code:**

☒ LFG (Tricyclic Antidepressant Test System)  
☒ JXN (Propoxyphene Test System)

**Regulation Section:**

21 CFR 862§ 3910  
21 CFR 862§3700

**Panel:**

Toxicology (91)

**PROPRIETARY INFORMATION**

~~Page 12 of 16~~



510(K) Submission for  
**UCP Rapid™ Drug Screening TCA, PPX Tests**

**Device Classification: II**

**Substantially Equivalent Devices:**

ACON TCA One Step Tricyclic Antidepressant Test  
Manufactured by ACON Laboratories

Instant -View® Propoxyphene (PPX) Urine Test  
Manufactured by Alfa Scientific Designs, Inc

**Product Description:**

UCP Rapid™ Drug Screening Tricyclic Antidepressant, Propoxyphene Tests are competitive binding, lateral flow immunochromatographic assays for qualitatively the detection of Tricyclic Antidepressant, Propoxyphene and their metabolites at the cut-off levels as indicated. The tests can be performed without the use of an instrument.

**Intended Use:**

UCP Rapid™ Drug Screening Tricyclic Antidepressant, Propoxyphene Test are rapid, qualitative, competitive binding immunoassays and intended for qualitatively the detection Tricyclic Antidepressant, Propoxyphene and their metabolites in human urine at the following cut-off concentrations:

Tricyclic Antidepressant	1000 ng/mL
Propoxyphene	300 ng/mL

The tests provide only preliminary test results, which should be confirmed by other methods such as gas chromatography/mass spectrometry (GC/MS). Clinical considerations and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated. The tests are not intended to be used in monitoring the drugs levels.

**Comparison to Predicate Devices:**

When compared to the predicates, UCP Rapid™ Drug Screening Tricyclic Antidepressant and Propoxyphene Tests provide the qualitative determination of the same drugs in the same matrix, and utilizes the same cutoff concentrations. Both tests are immunochromatographic, lateral flow assays for the qualitative detection of drugs with visual, qualitative end results. Both tests are intended to provide preliminary analytical test results.

**Safety and Effectiveness Data:**

**Accuracy**

**PROPRIETARY INFORMATION**

~~Page 43 of 55~~



510(K) Submission for  
**UCP Rapid<sup>TM</sup> Drug Screening TCA, PPX Tests**

A clinical comparison study was conducted using 128 clinical urine specimens per each drug including approximately 10% of the specimens containing one type drug at concentrations between -50% cutoff to cutoff ranges, another 10% of the specimens containing one type drug at concentrations between cutoffs to +50% cutoff ranges. The study was compared the test results between UCP Rapid<sup>TM</sup> Drug Screening Tricyclic Antidepressant Tests with ACON TCA One Step Tricyclic Antidepressant Tests, UCP Rapid<sup>TM</sup> Drug Screening Propoxyphene Test with Instant-View® Propoxyphene Urine test. Total 64 positive clinical urine specimens and 64 negative clinical urine specimens were tested against each drug. All test results were confirmed with HPLC or GC/MS analysis. UCP Rapid<sup>TM</sup> Drug Screening Tricyclic Antidepressant Test and UCP Rapid<sup>TM</sup> Drug Screening Propoxyphene Test demonstrated performance of  $\geq 98\%$  for all drugs when performance was compared to a legally marketed device and HPLC or GC/MS.

**Other Information about Performance Characteristics:**

The performance characteristics of UCP Rapid<sup>TM</sup> Drug Screening Tricyclic Antidepressant Test, UCP Rapid<sup>TM</sup> Drug Screening Propoxyphene Test was evaluated by precision study, sensitivity study, specificity and cross reactivity study, interference study and stability study. The study results indicate that UCP Rapid<sup>TM</sup> Drug Screening Tricyclic Antidepressant Test, UCP Rapid<sup>TM</sup> Drug Screening Propoxyphene Test performs satisfactorily when used according to the package inserts.

**Conclusion:**

UCP Rapid<sup>TM</sup> Drug Screening Tricyclic Antidepressant Test is substantially equivalent to ACON TCA One Step Tricyclic Antidepressant Test, UCP Rapid<sup>TM</sup> Drug Screening Propoxyphene Test is substantially equivalent to Instant-View® Propoxyphene (PPX) Urine Test.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
2098 Gaither Road  
Rockville MD 20850

Ms. Nancy Chen  
UCP Biosciences, Inc.  
1445 Koll Circle, Suite 111  
San Jose, CA 95112

AUG 21 2006

Re: k061457  
Trade/Device Name: UCP Rapid™ Drug Screening Tricyclic Antidepressant Test  
UCP Rapid™ Drug Screening Propoxyphene Test  
Regulation Number: 21 CFR§862.3910  
Regulation Name: Tricyclic antidepressant drugs test system  
Regulatory Class: Class II  
Product Code: LFG, JXN  
Dated: August 10, 2006  
Received: August 11, 2006

Dear Ms. Chen:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 –

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

A handwritten signature in black ink, appearing to read 'Alberto Gutierrez', with a stylized flourish at the end.

Alberto Gutierrez, Ph.D.  
Director  
Division of Chemistry and Toxicology  
Office of In Vitro Diagnostic Device  
Evaluation and Safety  
Center for Devices and  
Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known): K061457

Device Name: UCP Rapid™ Drug Screening Tricyclic Antidepressant Test  
UCP Rapid™ Drug Screening Propoxyphene Test

### Indications For Use:

The UCP Rapid™ Drug Screening Tricyclic Antidepressant Test and UCP Rapid™ Drug Screening Propoxyphene Test are rapid, qualitative, competitive binding immunoassays for the detection of Tricyclic Antidepressants, Propoxyphene and their metabolites in human urine at the following cutoff levels:

<u>Test</u>	<u>Calibrator</u>	<u>Cut-off</u>
Tricyclic Antidepressant	Nortriptyline	1000 ng/mL
Propoxyphene	Propoxyphene	300 ng/mL

The tests provide only preliminary data, which should be confirmed by other methods such as gas chromatography/mass spectrometry (GC/MS). The test configuration comes with either single drug test or in combination with multiple other drug tests. Clinical considerations and professional judgment should be applied to any drug of abuse test results, particularly when preliminary positive results are indicated. The tests are not intended to be used in monitoring drug levels.

Prescription Use   x  

AND/OR


Over-The-Counter Use

(Part 21 CFR 801 Subpart D)

(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

  
Division Sign-Off

Page ~~48~~ of ~~62~~

Office of In Vitro Diagnostic Device  
Evaluation and Safety

510(k) K061457